This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Earnings Valued Attractively (Teva)

NEW YORK (TheStreet) -- Teva Pharmaceutical (TEVA) -- founded in 1901 and headquartered in Israel -- is a worldwide pharmaceutical company with a mission to be "the most indispensible medicines company in the world."

Teva works across the board to develop, produce and market a wide range of products within specialty medicines, generic and over-the-counter products, active pharmaceutical ingredients and new therapeutic entities.

In the United States alone, Teva markets approximately 400 generic products in about 1,300 dosage strengths. The company also operates in 59 other countries across Europe and the rest of the world, and is perhaps best known for Copaxone, which is used to treat multiple sclerosis.

For those unfamiliar with the business behind the company, we can instantly look at Teva's past operating results through the lens of F.A.S.T. Graphs.

Here a picture is truly worth a magnitude of words. We see that Teva has grown operating earnings by nearly 24% a year for the past decade and a half and demonstrated a commitment to increasing the dividend while simultaneously keeping the earnings payout ratio quite low.

Additionally, it should be noted that Teva had exceptional earnings per share growth in the early 2000s and has since begun to moderate a bit. To be fair, even recently this pharmaceutical company has been able to grow earnings at a double-digit rate.

It follows that the return performance of Teva is also likely to be quite strong over the same period. This is precisely what we see: A shareholder beginning at the end of 1998 and holding until today would have seen capital appreciate over 15%, a dividend that grew by about 28% a year and total returns -- not to mention income provided -- that bested the S&P 50 five times over.

There's a reason that Teva recently showed up on a Value Line screen titled "Stocks for Dividend Growth With Low Risk."

The company has an absolutely excellent track record of returning shareholder value. Given this history, coupled with a low payout ratio and above-average dividend yield, it would seem that Teva is well poised to continue churning out profits for its shareholders.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs